- US-based clinical stage (Phase II ready) oncology drug development company.
- Indications: Multiple drug-resistant solid tumors; SCLC (Small cell lung cancer) without targets; NSCLC (Non small cell lung cancer); Colorectal cancer; Ovarian Cancer
- Accelerated drug development pathway for multiple drug-resistant tumors.
- A novel, patented drug-to-drug conjugate of Topoisomerase I and II dual inhibitors.
- Favorable safety and efficacy in patients with solid tumor who were resistant to previous chemotherapy, radiation therapy and immunotherapy.
Address
Newport BeachCalifornia
United States
